Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage
June 11, 2024 – Biotechnology, Clinical Trials, Drug Discovery – Asgard Therapeutics, Exothera, clinical trials, immunotherapy, viral vectors
11 June 2024 — Lund, Sweden — Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announced it selected Exothera, a leading provider of nucleic acids and viral vector development and manufacturing services, for process development up to clinical phases 1/2 manufacturing of its candidate AT-108, based on viral vector technology.
AT-108 is a first-in-class, off-the-shelf gene therapy that leads to personalised and potent anti-cancer immune responses. AT-108 reprogrammes cancer cells inside the patient’s body to become conventional Type 1 Dendritic Cells (cDC1s), a rare subset of immune cells, which are critical for effective anti-tumour immunity. These induced cDC1s present the individual’s specific cancer antigens to the immune system, triggering personalised and systemic anti-cancer immune responses.
Exothera will be entrusted with the development and scale-up of a manufacturing process for the drug candidate, including development of analytical methods, GMP-grade material production and aseptic filling.
Exothera offers a full-service model for viral vector-based biotherapeutics thanks to state-of-the-art technologies, and one of the largest viral vector facilities in Europe (15,000m² – 161,500ft²).
Cristiana Pires, co-founder and chief executive officer of Asgard Therapeutics, said: “Following our proof-of-concept studies supporting the lead candidate AT-108, we are very happy to reach process development phase and start CMC activities. We are looking forward to work with the very knowledgeable and skilled technical team at Exothera to progress our pioneering AT-108 towards clinical development.”
Hanna Lesch, chief technology officer at Exothera, mentioned: “We are proud to support Asgard Therapeutics in bringing these revolutionary therapeutics closer to the patients. Over the years we gained extensive experience with virus-based therapeutics production – both in suspension and in fixed bed bioreactors – and we are confident that we will use this expertise to help Asgard Therapeutics achieve clinical phase success.”
About Asgard Therapeutics
Asgard Therapeutics is a privately held preclinical stage biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy. The company builds on ground-breaking and proprietary reprogramming technologies to develop gene therapy products designed to set in motion efficient and personalised immune responses. Backed by Johnson & Johnson Innovation – JJDC, Inc, RV Invest, Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to establish a pipeline of off-the shelf cancer immunotherapies that trigger personalised anti-cancer immune responses for the benefit of cancer patients in need. For more information, please visit: www.asgardthx.com
About Exothera
Exothera is a contract, development and manufacturing organisation (CDMO) dedicated to viral vector and nucleic acids production. As a technology-driven company, Exothera provides best-in-class bioprocessing expertise that capitalises on the best and most innovative manufacturing technologies developed within the Univercells group. The company delivers accelerated discovery services as well as process development/optimisation to rapidly reach GMP clinical and commercial production of vaccines, viral vectors, oncolytic viruses and nucleic acids. At Exothera and Univercells, our mission is to make life-changing therapies available to all. For more information, visit www.exothera.world.
